新闻稿

New Studies by Intermountain Healthcare's Intermountain Precision Genomics Reveal that Precision Medicine Improves Survival in Advanced Cancer Patients without Increasing Costs

将于5月29日在美国临床肿瘤学会年会上公布的研究

SALT LAKE CITY,Utah,5月29日,二千零一十五intermountain healthcare的intermountain precision genomics进行的两项新研究表明,精确药物可以提高晚期癌症患者的生存率,而且不会增加成本。虽然这些结果只影响到4期癌症患者生命的最后几周,the improvement is pronounced and lends hope that further improvement can be realized going forward.这些研究将通过美国临床肿瘤学会年会以摘要形式发表。(ASCO) in Chicago.

Intermountain Healthcare,an internationally recognized,integrated healthcare system spanning 22 hospitals and 185 physician clinics,是通过山间精密基因组学进行个性化癌症治疗的前沿。Led by Lincoln D.Nadauld,MD,PhD,Derrick S.Haslem,MD,Intermountain Precision Genomics in St.乔治,UT,is the only integrated healthcare system in the nation with the capability of testing and providing treatment for the greatest number of actionable gene mutation types,提供最先进的下一代测序技术。Intermountain is typically able to gain access to limited distribution and specialty drugs for its patients.

Intermountain Precision Genomics' expertise is enhanced by the fact that Intermountain Healthcare has the nation's largest biorepository,started in 1975,which stores more than three million tissue samples used for the advancement of cancer and other research.

在山间精密基因组学内部实验室,experts analyze theDNAand genetic makeup of a cancer patient's tumor,能够检测出癌症中存在错误的单个基因,从而确定治疗方案。The testing is proprietary to Intermountain Healthcare but access to it is available to oncologists anywhere.The testing serves patients with stage four cancer who have failed a traditional treatment method.

Following are the two new studies that Intermountain Precision Genomics will present atASCOon May 29:

"Precision Medicine To Improve Survival Without Increasing Costs In Advanced Cancer Patients"– This study finds that "progression free survival was 22.9 weeks for the treatment group and 12.0 weeks for the historical control group (p = 0.002).Patients receiving precision cancer medicine compared to conventional treatment patients had a hazard ratio of 0.47 (95% confidence interval of 0.29-0.75) when adjusting for age,gender,histological diagnosis and previous treatment lines.Costs per week were $3204 in the targeted group and $3501 in the control cohort (p = 0.385)" The study concludes,"Precision cancer medicine appears to significantly improve survival for patients with advanced cancer when compared to control patients who received conventional chemotherapy.The additional survival is not associated with increased healthcare costs.While the results of this study warrant further investigation in the setting of a prospective randomized control trial,this genomics-based approach appears to be a viable,and perhaps superior,option for patients with advanced or metastatic cancer."

"Implementation of a precision cancer program in an integrated health care system"– This study finds that "243 patients with a variety of tumor types have hadNGSperformed on their tumor as part of our precision cancer clinic.188 patients (77%) had actionable mutations.This resulted in a treatment change to the targeted drug in 117 patients (62%).In addition,38 patients (20%) have targeted options available,but are awaiting disease progression through their current treatment.Our drug navigation system has successfully obtained drug for 155 patients (82%) through insurance approval,上诉程序或临床试验。“研究结论,“尽管精确癌症诊所存在障碍,they can be overcome in the community setting through appropriate implementation ofNGS,access to aMTBand a drug procurement process.In the era of personalized medicine,this model offers improved access to genomic medicine for advanced cancer patients outside of the academic setting."

"These results are significant and encouraging," said Dr.Nadauld,Medical Director of Intermountain Precision Genomics.“他们强调了当今精确医学对患者的价值,offering increased survival without increasing costs."

"The challenge now is to build on these results," added Dr.Haslem,Director of Medical Oncology at Intermountain Precision Genomics.“这些研究所强化的方向具有巨大的潜力,if we can extend it further."

Nearly 80% of the patients treated at Intermountain Precision Genomics have been connected to targeted drug therapies.没有其他医疗体系有过类似的成功。Unlike traditional chemotherapy,重点是摧毁快速分裂的细胞,有针对性的治疗可以识别出对癌细胞更为特异的其他特征。These medications work in individual ways,but all interfere with the ability of the cancer cell to grow,divide,repair,and/or communicate with other cells.

About Intermountain Healthcare

Intermountain Healthcare是一个位于犹他州的非营利系统,由22家医院、185家诊所、一个拥有约1100名受雇医师的医疗集团组成。一个叫做SelectHealth健康计划部门,以及其他卫生服务。Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs.  For more information about Intermountain,visitwww.intermountainhealthcare.org.

[阅读原文Intermountain Healthcare's site.We're proud to have Intermountain as a customer!]